While the UPR was not among the top downregulated pathways in NHD MDMi when compared to controls, we explored it in more detail to assess potential similarities and differences in MDMi derived from monoallelic TYROBP deletion carriers and NHD patients in comparison to controls. This evidence concerns the gene TYROBP and Nasu-Hakola disease.